AC
EGRX

Armistice Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Armistice Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150,000
Closed -$6.67K – 241
2022
Q2 		$6.67K Sell
150,000
-74,000
-33% -$3.4M 0.12% 92
2022
Q1 		$11.1M Buy
+224,000
New +$10.8M 0.21% 72
2021
Q2 		– Sell
-192,000
Closed -$8.01M – 145
2021
Q1 		$8.01M Sell
192,000
-172,000
-47% -$7.99M 0.18% 83
2020
Q4 		$17M Sell
364,000
-308,000
-46% -$14.4M 0.58% 53
2020
Q3 		$28.5M Buy
672,000
+390,000
+138% +$17.1M 1.04% 37
2020
Q2 		$13.5M Buy
+282,000
New +$14.1M 0.59% 58

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return